New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
Immunization <strong>Update</strong><br />
March 24, <strong>2011</strong> Approval Letter – Zostavax for patients<br />
age 50-59 years<br />
• Compared with placebo, ZOSTAVAX significantly<br />
reduced the risk of developing zoster by 69.8% (95%<br />
CI [54.1 - 80.6%]) in 22,439 subjects 50 to 59 years of<br />
age. Data from the Shingles Prevention Study<br />
demonstrated 64% (95% CI 56-71%) efficacy in<br />
patients age 60-69 years and 41% (95% CI 28 -52%)<br />
efficacy for patients age 70-79 years and. only 18%<br />
(95% CI -29 – 48%) efficacy in patients age 80 and<br />
above.<br />
<strong>New</strong> Influenza Vaccine<br />
• MAY 10, <strong>2011</strong> The FDA has approved the first Fluzone<br />
Intradermal vaccine for adults 18 through 64 years old. It will<br />
be available for the <strong>2011</strong>-12 influenza season.<br />
– Sanofi Pasteur's new product has a needle less than a<br />
tenth of an inch long, attached to a pre-filled syringe that<br />
holds a smaller amount of influenza vaccine than the<br />
company' standard flu shots.<br />
– patients have said they prefer the shorter, slimmer needles<br />
of the Fluzone Intradermal vaccine, but there's no data yet<br />
on whether they are less painful<br />
– Reactions around the injection site, including redness,<br />
swelling and itching, were more common with the new<br />
vaccine than with an intramuscular vaccine, company<br />
research found.<br />
Wayne Weart<br />
<strong>New</strong> <strong>Drug</strong> <strong>Update</strong> Part I